ON THE PEN · Jul 17, 2026
Boehringer’s Next Obesity Bet Not Just Another Incretin, It’s One of the Brain’s Most Powerful Hunger Pathways
0Sign in to vote or save
Over the past few years, we’ve watched obesity medicines evolve from our favorite GLP-1 therapies we discuss like semaglutide, or dual agonists like tirzepatide, and now to triple agonists like retatrutide.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.